サイケデリックドラッグ市場- 世界の産業規模、シェア、動向、機会、予測、2018年-2028年、薬剤タイプ別、用途別、流通チャネル別、地域別、競合予測・機会

世界のサイケデリックドラッグ市場は予測期間中に目覚ましい成長を遂げると予測されています。

世界のサイケデリックドラッグ市場は、主に研究の進歩、これらの物質に対する認識の変化、潜在的な治療用途によって、関心の高まりと成長の復活を経験しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のサイケデリックドラッグ市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 薬物タイプ別（リゼルギン酸ジエチルアミド、γ-ヒドロキシ酪酸、ケタミン、シロシビン、その他）
  • 用途別（治療抵抗性うつ病、アヘン中毒、心的外傷後ストレス障害、ナルコレプシー、パニック障害、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • 薬剤タイプ別
  • 用途別
  • 流通チャネル別
  • 地域別

第6章 北米のサイケデリックドラッグ市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬物タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のサイケデリックドラッグ市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 薬物タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋のサイケデリックドラッグ市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 薬物タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米のサイケデリックドラッグ市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 薬物タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのサイケデリックドラッグ市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬物タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Jazz Pharmaceuticals PLC
• NeonMind Biosciences Inc.
• Cybin Inc.
• Pfizer Inc
• Numinus Wellness Inc
• Mind Medicine Inc
• PharmaTher Holdings Ltd
• NRX Pharmaceuticals Inc
• Seelos Therapeutics Inc
• Revive Therapeutics Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Psychedelic Drug Market is anticipated to project impressive growth in the forecast period. The global psychedelic drug market has been experiencing a resurgence of interest and growth, primarily driven by advancements in research, changing perceptions of these substances, and their potential therapeutic applications.

Key Market Drivers

Therapeutic Potential and Research Breakthroughs

The foremost way in which therapeutic potential and research breakthroughs are boosting the growth of the global psychedelic drug market is by unveiling novel and highly effective treatment avenues. Clinical trials and studies have shown promising results in using psychedelics like psilocybin, MDMA, and LSD to treat a range of mental health disorders, including depression, anxiety, PTSD, and addiction. These breakthroughs offer new hope to patients who have struggled with conventional therapies, and as a result, there is a growing demand for psychedelic-assisted therapies.

The promise of these breakthrough therapies has attracted significant investment and funding from a diverse range of sources. Venture capital firms, pharmaceutical companies, and philanthropic organizations are pouring resources into research and development efforts within the psychedelic drug market. This influx of capital is accelerating the pace of research, development, and clinical trials, propelling the market's growth.

The therapeutic potential of psychedelics is leading to progressive changes in the regulatory landscape. Regulatory bodies in various countries, including the United States and Canada, are recognizing the significance of these findings. They have granted breakthrough therapy designations and have initiated steps to facilitate research and clinical trials. Such regulatory support is a pivotal factor that encourages pharmaceutical companies and researchers to further invest in psychedelic drug development.

Another crucial way in which therapeutic potential and research breakthroughs boost market growth is by reducing the stigma associated with psychedelics. As the scientific community continues to present compelling evidence of their efficacy in treating mental health disorders, public perception is shifting. People are increasingly viewing these substances as valuable tools for healing and personal growth rather than as mere recreational drugs. This changing perspective is contributing to a more receptive and accepting environment for psychedelic therapies.

Research breakthroughs are not confined to the efficacy of psychedelic compounds alone. They are also driving innovation in treatment delivery methods. Researchers and pharmaceutical companies are exploring various delivery mechanisms such as nasal sprays, patches, and lozenges to enhance the precision and safety of dosing. These innovations are making psychedelic-assisted therapy more accessible and user-friendly, further boosting market growth.

The ongoing global mental health crisis, exacerbated by the COVID-19 pandemic, has emphasized the urgent need for effective treatments. Traditional approaches to mental health care, such as antidepressants, do not work for everyone and often come with unwanted side effects. The therapeutic potential of psychedelics offers an alternative and more holistic approach to mental health treatment, aligning with the growing demand for effective solutions.

Changing Regulatory Landscape

One of the most critical factors contributing to the growth of the psychedelic drug market is the increasing recognition of the therapeutic potential of these substances by regulatory agencies worldwide. Psychedelics such as psilocybin (found in magic mushrooms) and MDMA have shown remarkable promise in clinical trials for treating mental health disorders like depression, anxiety, PTSD, and addiction. As regulatory bodies acknowledge these findings, they are more willing to facilitate research and streamline the approval process for psychedelic-assisted therapies, thus fostering market growth.

In the United States, the Food and Drug Administration (FDA) has granted "breakthrough therapy" status to certain psychedelic therapies, including psilocybin-assisted treatment for depression. This designation acknowledges the significant therapeutic potential of these treatments and expedites their development and regulatory approval. The expedited pathways not only save time and resources but also encourage further investment and research within the industry.

Some regions and countries have gone beyond facilitating research and have taken steps towards decriminalization or even legalization of certain psychedelic substances. For instance, Oregon became the first U.S. state to legalize the regulated medical use of psilocybin, signaling a profound shift in drug policy. Such measures open up new markets and provide opportunities for businesses to operate legally, thus boosting market growth.

The evolving regulatory landscape has also led to increased international collaborations in psychedelic research. Researchers and companies are partnering with institutions and experts across borders to conduct studies and clinical trials. This global cooperation accelerates the pace of research, ensuring that promising therapies reach the market more quickly.

The changing regulatory environment has bolstered investor confidence in the psychedelic drug market. Venture capital firms and private investors are more willing to invest in companies and research initiatives within this sector, as they see a clearer path to regulatory approval and market entry. This influx of capital is vital for advancing research and driving market growth.

As regulatory bodies become more supportive of psychedelic research, it contributes to mainstream acceptance of these substances. Public perception is shifting, with many individuals viewing psychedelics as legitimate tools for healing and personal growth, rather than just recreational drugs. This increased acceptance not only reduces stigma but also drives demand for accessible and safe psychedelic therapies.

Diverse Treatment Approaches

Traditionally, psychedelic substances have been consumed orally or through intravenous injection. However, innovative treatment approaches are expanding the range of options available. Researchers and pharmaceutical companies are exploring alternative modalities such as nasal sprays, patches, lozenges, and even controlled-release formulations. These diverse administration methods aim to improve the precision and consistency of dosing, enhance patient comfort, and provide healthcare professionals with more flexibility in tailoring treatment regimens.

Diverse treatment approaches are not just about convenience; they also hold the potential to enhance the therapeutic efficacy of psychedelic therapies. For example, controlled-release formulations can provide a prolonged and steady release of the active substance, potentially prolonging therapeutic effects and reducing the need for frequent dosing. This innovation can be especially beneficial in the treatment of chronic mental health conditions, leading to better patient outcomes and satisfaction.

Every patient is unique, and their response to treatment can vary significantly. Diverse treatment approaches allow for greater personalization of psychedelic-assisted therapy. Healthcare providers can tailor the choice of administration method to an individual's specific needs, preferences, and medical history. This personalized approach can lead to more effective treatments, improved patient compliance, and overall better results.

The availability of diverse treatment approaches is helping to make psychedelic therapies more accessible and acceptable to a broader range of patients. Some individuals may be hesitant to participate in traditional psychedelic experiences involving the consumption of substances like psilocybin or LSD. However, the development of less invasive administration methods, such as nasal sprays or lozenges, can make the therapeutic process seem less daunting and more appealing to a wider audience.

Innovation in treatment approaches also has the potential to mitigate some of the risks associated with psychedelic therapy. Controlled-release formulations and precise dosing methods can help reduce the likelihood of adverse reactions or misuse. This added safety and predictability can lead to greater acceptance among regulators and healthcare professionals, further supporting market growth.

Diverse treatment approaches open up opportunities to explore new target markets beyond traditional psychiatric settings. As psychedelics become available in forms that can be administered outside of clinical environments, wellness centers, retreats, and even at-home settings may become viable options for delivering psychedelic-assisted therapies. This expansion of potential treatment locations can significantly broaden the market's reach.

Rising Mental Health Concerns

The COVID-19 pandemic has exacerbated pre-existing mental health issues and triggered new ones for many individuals. The effects of lockdowns, social isolation, economic hardship, and the fear of illness have contributed to skyrocketing rates of anxiety, depression, PTSD, and substance abuse. As traditional treatments often fall short in providing effective relief for these conditions, there is an urgent need for alternative therapeutic approaches.

Research and clinical trials have shown that psychedelic substances like psilocybin (found in magic mushrooms), MDMA, and LSD have the potential to offer profound and lasting relief for individuals suffering from mental health disorders. These substances work on a neurobiological level to create therapeutic experiences that can lead to breakthroughs in understanding and coping with one's mental health challenges. As more people seek alternatives to traditional therapies, the demand for psychedelic-assisted treatments grows.

The rising mental health concerns have prompted a reevaluation of the stigma surrounding psychedelics. Increasingly, these substances are being seen as legitimate tools for addressing mental health issues rather than mere recreational drugs. As more individuals, healthcare professionals, and policymakers acknowledge the potential benefits of psychedelic therapies, the stigma diminishes, making it easier for patients to seek and access these treatments.

Psychedelic therapies often take a more holistic approach to mental health treatment. They address not only the symptoms but also the underlying causes of mental health disorders. This comprehensive approach aligns with the growing demand for treatments that consider the whole individual and not just the immediate symptoms, contributing to the growth of the psychedelic drug market.

The urgency of the mental health crisis has caught the attention of investors and pharmaceutical companies. As the potential of psychedelics becomes more apparent, they are directing substantial funding towards research, development, and clinical trials. This influx of capital is accelerating the pace of innovation in the psychedelic drug market and driving its growth.

Key Market Challenges

Regulatory Hurdles

Perhaps the most significant challenge facing the psychedelic drug market is the complex and evolving regulatory landscape. Many psychedelics are classified as controlled substances due to their historical association with recreational use and concerns about safety and abuse potential. Navigating these regulations can be a lengthy and expensive process, often requiring years of clinical trials and regulatory approvals.

Safety Concerns

Safety is a paramount concern in the development of any drug, and psychedelics are no exception. While research has shown promising results in controlled settings, there are still potential risks associated with these substances, including adverse reactions and psychological distress. Ensuring the safety and well-being of patients during psychedelic-assisted therapy is a top priority.

Key Market Trends

Integration of Psychedelic Therapies into Mainstream Healthcare

As the therapeutic potential of psychedelics becomes increasingly evident, a trend is emerging where psychedelic therapies are integrated into mainstream healthcare systems. This includes collaborations between psychedelic clinics and established medical institutions, as well as the inclusion of these therapies in treatment guidelines for mental health disorders. Such integration is expected to make these therapies more accessible to a broader range of patients.

Psychedelic-Assisted Digital Therapeutics

The convergence of psychedelics and digital technology is opening up new possibilities in mental health treatment. Companies are developing psychedelic-assisted digital therapeutics that combine the use of psychedelic substances with digital tools, such as virtual reality (VR) or augmented reality (AR), to enhance the therapeutic experience. These technologies can create immersive and controlled environments for therapy sessions and aid in patient monitoring and progress tracking.

Segmental Insights

Drug Type Insights

Based on the category of Drug Type, Psilocybin is poised to dominate the global psychedelic drug market in 2022 due to a convergence of factors that make it a frontrunner in the industry. Firstly, increasing awareness of the therapeutic potential of psilocybin in treating various mental health conditions, such as depression, anxiety, and PTSD, has led to a growing demand for psilocybin-based treatments. Moreover, recent regulatory changes in several countries and regions have facilitated research and development efforts, paving the way for potential legalization and commercialization. Additionally, the growing interest from both pharmaceutical companies and venture capitalists has injected significant capital into the psilocybin sector, fostering innovation and accelerating its market growth. As research continues to uncover the vast therapeutic possibilities of psilocybin, its prominence in the global psychedelic drug market is expected to solidify, offering immense opportunities for businesses and investors alike.

Distribution Channel Insights

The hospital pharmacy segment is poised for expansion in the foreseeable future due to several key factors. These include the rising awareness of mental health issues among the general population, the prescription-based nature of psychedelic drugs, and their application for specific medical conditions, all contributing to the increasing prominence of hospital pharmacies as distribution channels.

The global prevalence of mental health disorders, notably depression and anxiety, has created a pressing need for effective mental health management to enhance overall well-being. The utilization of psychedelic drugs in treating such conditions is expected to fuel market growth significantly. For instance, according to the 2022 report by Mental Health America, the number of individuals in Texas affected by mental illness reached 3.6 million in 2022. With a surge in mental health cases, there is a corresponding increase in the use of psychedelic drugs, thereby bolstering market growth. Consumers prefer hospital pharmacies as trusted sources for obtaining authorized and safe prescription drugs, contributing to the expansion of this distribution channel.

Psychedelic drugs, known for their potency, fall under the category of prescription medications. In countries like India, substances such as ketamine are categorized as 'Schedule X' drugs, requiring a qualified doctor's prescription and making them unavailable over the counter. Consequently, as psychedelic drugs necessitate a medical practitioner's prescription, they are predominantly dispensed through hospital pharmacies, further augmenting the growth of this specific market segment.

Regional Insights

North America is poised to maintain a significant share in the global psychedelic drugs market, a trend expected to persist throughout the forecast period. This prominence can be attributed to the region's robust research and development initiatives focused on psychedelic drugs, a heightened awareness surrounding mental health treatment, and the escalating incidence of mental health disorders. For instance, according to the 2022 Adult Prevalence of Mental Illness (AMI) statistics, a staggering 19.86% of adults in North America grapple with mental illness, equating to nearly 50 million Americans, with 4.91% experiencing severe mental health conditions. These alarming prevalence rates underscore the pressing demand for psychedelic drugs as a therapeutic solution, thereby propelling market growth over the projected timeframe.

Furthermore, the increasing consciousness regarding mental health issues necessitating treatment with psychedelic drugs is anticipated to be a catalyst for market expansion. A notable example is the Mental Illness Awareness Week conducted by the Canadian Government in October 2022-a national campaign aimed at dispelling misconceptions about mental illness, enhancing public understanding of mental health, and reducing stigma while promoting acceptance and equitable treatment for individuals dealing with mental health challenges. These awareness campaigns are expected to elevate the demand for medications, contributing to market growth in the coming years.

Moreover, the proliferation of company expansions and the establishment of psychedelic treatment centers are set to significantly bolster regional market growth. For instance, in March 2022, the Canada-based Delic Corporation expanded its Ketamine Wellness Centers (KWC) to include new locations in Salt Lake City and Reno, equipped with FDA-approved SPRAVATO (esketamine) treatment options. Such initiatives are poised to further invigorate the North American psychedelic drugs market.

Key Market Players

Jazz Pharmaceuticals PLC

NeonMind Biosciences Inc.

Cybin Inc.

Pfizer Inc

Numinus Wellness Inc

Mind Medicine Inc

PharmaTher Holdings Ltd

NRX Pharmaceuticals Inc

Seelos Therapeutics Inc

Revive Therapeutics Inc

Report Scope:

In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychedelic Drug Market, By Drug Type:

• Lysergic Acid Diethylamide
• Gamma Hydroxybutyric Acid
• Ketamine
• Psilocybin
• Others

Psychedelic Drug Market, By Application:

• Treatment-Resistant Depression
• Opiate Addiction
• Post-Traumatic Stress Disorder
• Narcolepsy
• Panic Disorders
• Others

Psychedelic Drug Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Psychedelic Drug Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.

Available Customizations:

• Global Psychedelic Drug market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychedelic Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 5.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Application
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Psychedelic Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 6.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psychedelic Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Psychedelic Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Psychedelic Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Psychedelic Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 7.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psychedelic Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Psychedelic Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France Psychedelic Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Psychedelic Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Psychedelic Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Psychedelic Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 8.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Psychedelic Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Psychedelic Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India Psychedelic Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Psychedelic Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea Psychedelic Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Psychedelic Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 9.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Psychedelic Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Psychedelic Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Psychedelic Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Psychedelic Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 10.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Psychedelic Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Psychedelic Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Psychedelic Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait Psychedelic Drug Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Type
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Jazz Pharmaceuticals PLC
  • 14.6.2. NeonMind Biosciences Inc.
  • 14.6.3. Cybin Inc.
  • 14.6.4. Pfizer Inc
  • 14.6.5. Numinus Wellness Inc
  • 14.6.6. Mind Medicine Inc
  • 14.6.7. PharmaTher Holdings Ltd
  • 14.6.8. NRX Pharmaceuticals Inc
  • 14.6.9. Seelos Therapeutics Inc
  • 14.6.10. Revive Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer